A pharmaceutical company has been given a grant to develop a new drug that may one day treat Alzheimer's disease and other neurodegenerative conditions.
Yesterday, Varinel, Inc. was given $185,000 for the development of its "multifunctional lead compounds," which tested successfully in animals with Alzheimer's.
The grant was made possible by the Alzheimer's Drug Discovery Foundation (ADDF), a public charity dedicated to finding new medications for the treatment of Alzheimer's disease.
"The multifunctional approach shows great promise and, if successful, may yield an entirely new class of drugs for treatment of Alzheimer's disease and other neurodegenerative diseases such as Parkinson's disease, Huntington's disease and ALS."
This may be especially good news for Alzheimer's patients following news that a study found the herbal supplement ginkgo biloba offered no protection towards the condition.
Those looking for a way to possibly reduce the risk of Alzheimer's can go outside for a walk. A recent article in Scientific American suggested regular exercise could deter the disease.
An estimated 5.2 million people in the U.S. are currently living with Alzheimer's disease. By 2030, it's estimated the number of individuals age 65 and older with the disease will reach 7.7 million.